The effect of long-acting cabotegravir and rilpivirine treatment on drug resistance in South Africa: a modelling study
US National Institutes of Health National Institute of Allergy and Infectious Diseases and the Swiss National Science Foundation.
Authors
- Nanina Anderegg (ORCID: https://orcid.org/0000-0002-8238-8832)
- Mary‐Ann Davies (ORCID: https://orcid.org/0000-0001-8496-6475)
- Leigh F. Johnson (ORCID: https://orcid.org/0000-0002-2717-011X)
- Huldrych F. Günthard (ORCID: https://orcid.org/0000-0002-1142-6723)
- Richard Lessells (ORCID: https://orcid.org/0000-0003-0926-710X)
- Roger D. Kouyos (ORCID: https://orcid.org/0000-0002-9220-8348)
- Tom Loosli (ORCID: https://orcid.org/0000-0003-2049-3562)
- Matthias Egger (ORCID: https://orcid.org/0000-0001-7462-5132)
- Anthony Hauser (ORCID: https://orcid.org/0000-0002-7221-1929)
- Johannes Josi
- Nuri Han (ORCID: https://orcid.org/0000-0001-6279-5150)
Institutions
- University of Bern (CH)
- University of Cape Town (ZA)
- Institute of Social and Preventive Medicine (CH)
- Centre universitaire de médecine générale et santé publique, Lausanne (CH)
Publication Details
- Journal
- The Lancet Global Health
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1016/s2214-109x(25)00350-x
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00